|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
Fluorouracil (5-FU) for nonmelanoma skin cancer - [Medication] - Quest Diagnostics Patient Health Library
Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Fluorouracil (5-FU) for nonmelanoma skin cancer - [Medication] - Quest Diagnostics Patient Health Library Fluorouracil (5-FU) for nonmelanoma skin cancer - [Medication] - Quest Diagnostics Patient Health Library Cancer, Skin, hair, and nails, 5-...
|
|
|
Fluorouracil (5-FU) for genital warts (human papillomavirus) - [Medication] - Quest Diagnostics Patient Health Library
Fluorouracil (5-FU) for genital warts (human papillomavirus) Examples Brand Name Chemical Name Efudex, Fluoroplex fluorouracil (5-FU) Fluorouracil has not been approved by the U.S.
A woman should use birth control to prevent pregnancy during fluorouracil therapy because it can be harmful to the fetus.
Topic Contents - Examples - How It Works - Why...
|
|
|
Dusa 2004 page 21
author: Tracey Watt
duplicates:
http://www.dusapharma.com/pdf/DUSA_10K_04.pdf
|
|
|
http://www.fda.gov/cder/orange/appendix_a.txt
400, ERYTHROMYCIN ETHYLSUCCINATE E.E.S., ERYTHROMYCIN ETHYLSUCCINATE EC-NAPROSYN, NAPROXEN ECONAZOLE NITRATE, ECONAZOLE NITRATE ECONOCHLOR, CHLORAMPHENICOL ECONOPRED PLUS, PREDNISOLONE ACETATE ECONOPRED, PREDNISOLONE ACETATE EDECRIN, ETHACRYNATE SODIUM EDECRIN, ETHACRYNIC ACID EDETATE DISODIUM, EDETATE DISODIUM EDEX, ALPROSTADIL EDROPHONIUM CHLORIDE PRESERVATIVE FREE, EDROPHONIUM...
|
|
|
2001 Warning Letters and Untitled Letters to Pharmaceutical Companies
Food and Drug Administration • Center for Drug Evaluation and Research Compliance Activities Search Warning Letters and Untitled Letters to Pharmaceutical Companies 2001 These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office
- [ 2004 ] [ 2003 ][ 2002 ] 2001 [ 2000 ] [ 1999 ] [ 1998 ] [ 1997 ] December 2001 Product Company Released...
|
|
|
http://www.int-med.uiowa.edu/Intranet/Residents/xToDelete/GMedCurricOld/Jan-Jun%2004/actinickeratoses/57.pdf
the general population of women of childbearing age, 3- 4 with levonorgestrel- containing OCs and 6- 8 with desogestrel or gestodene, approaching 1 per 1,000 among new users of thirdgeneration progestins during the first year of use (H Jick et ai, BMJ 2000; 321: 1190; JP Vandenbroucke et ai, N Engl J Med 2001; 344: 1527).
' " ,.,- ;0 ' \ NEW TREATMENTS FOR ACTINIC KERATOSES ~ (f["...
author: floerchingerd [ M68498 ]
duplicates:
http://www.int-med.uiowa.edu/Intranet/Residents/xToDelete/GMedCurricOld/Jan-Jun%2004/ActinicKeratoses/57.pdf
|
|
|
http://www.int-med.uiowa.edu/Intranet/Residents/xToDelete/GMedCurricOld/Jan-Jun%2004/actinickeratoses/57.pdf page 1
author: floerchingerd [ M68498 ]
duplicates:
http://www.int-med.uiowa.edu/Intranet/Residents/xToDelete/GMedCurricOld/Jan-Jun%2004/ActinicKeratoses/57.pdf
|
|
|
Prescription and Over-the-Counter Drug Product List: 11/2003
ACTHAR GEL >D> BC + QUESTCOR PHARMS 80 UNITS/ML N08372 008 NOV CTEC >A> + 80 UNITS/ML N08372 008 NOV CTEC CYTARABINE INJECTABLE; INJECTION >D> CYTARABINE >D> AP + GENSIA SICOR PHARMS 100MG/VIAL N16793 001 NOV DISC >D> AP + 500MG/VIAL N16793 002 NOV DISC >D> AP + 1GM/VIAL N16793 003 DEC 21, 1987 NOV DISC >D> AP + 2GM/VIAL N16793 004 DEC 21, 1987 NOV DISC >A> @ SICOR PHARMS 100MG/VIAL...
|
|
|
Cancer.gov - Nausea and Vomiting (PDQ®)
The American Society of Clinical Oncology (ASCO) has developed a rating system for chemotherapeutic agents and their respective risk of acute and delayed emesis.[ 1 ] High-risk cisplatin: Emesis that has been documented to occur in more than 99% of patients: cisplatin (Platinol) High-risk noncisplatin: Emesis that has been documented to occur in 30% to greater than 90% of patients:...
|
|
|
Microsoft Word - Medication_Listing.doc
Continuing Care Pharmacy & Therapeutics Formulary ML- 01 SECTION SUBJECT Page 1 of 38 MEDICATION LISTING (ML) Medication Listing YY MM DD Original 00 10 30 Revised 02 01 14 Revised 03 10 23 4: 00 Antihistamine Drugs cetirizine (Reactine®, Apo- cetirizine®) 10 mg tab common cold preparations Autosubstitution to Actifed (ASL– 01) cyproheptadine (Periactin®) 4 mg tab...
author: Wendy Daws
|
|
|
Microsoft Word - Medication_Listing.doc page 35
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc
025% (Synalar®, Synamol®) Autosubstitution to betamethasone valerate 0.1% (ASL- 34 84: 06 fluocinonide 0.01% (Lidex®) Autosubstitution for intermediate potency topical corticosteroids (ASL – 01) 33 84: 06 fluocinonide 0.05% (Lidex®) Autosubstitution for high potency topical corticosteroids (ASL – 01) 33 84: 06 fluorouracil (5- FU®, Efudex...
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc page 20
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc page 2
author: Wendy Daws
|
|
|
Microsoft Word - Master_Index.doc
025% (Synalar®, Synamol®) Autosubstitution to betamethasone valerate 0.1% (ASL- 01) 34 84: 06 fluocinonide 0.01% (Lidex®) Autosubstitution for intermediate potency topical corticosteroids (ASL – 01) 33 84: 06 fluocinonide 0.05% (Lidex®) Autosubstitution for high potency topical corticosteroids (ASL – 01)----- 33 84: 06 fluorouracil (5- FU®, ...
author: Wendy Daws
|
|
|
APPROVED LABELING NDA 20-985/S-0001
Three patients who received Carac and nine patients who received Efudex® 5% Cream had measurable plasma fluorouracil levels; however, only one patient receiving Carac and six patients receiving NDA 20- 985/ S- 001 Efudex® 5% Cream had a sufficient number of data points to calculate mean pharmacokinetic parameters
hr/ mL Five of 10 patients receiving...
author: JFG
subject: CARAC CREAM (FLUOROURACIL CREAM)
|
|
|
APPROVED LABELING NDA 20-985/S-0001 page 10
author: JFG
subject: CARAC CREAM (FLUOROURACIL CREAM)
|
|
|
APPROVED LABELING NDA 20-985/S-0001 page 2
author: JFG
subject: CARAC CREAM (FLUOROURACIL CREAM)
|
|
|
APPROVED LABELING NDA 20-985/S-0001 page 1
author: JFG
subject: CARAC CREAM (FLUOROURACIL CREAM)
|
|
|
Positive Touch XP TDS
Positive Touch XP extra protection powder- free latex exam gloves Gloves Produc s Ca
26 Palm Thickness (mil/ mm): 11
30 Barrier Pro ec ion With respect to gloves, cceptable Quality Level ( QL) for freedom from holes refers to co fide ce i protectio
RAST Resul s (µg/ gm): 4 Powder Level Positive Touch® XP exam gloves meet the requireme t for a powder- free glove per...
author: Lisa Gallagher
|
|
|
Positive Touch XP TDS page 2
author: Lisa Gallagher
|
|
|
4:00 page 16
author: Christine Wildman
|
|
|
4:00 page 37
author: Christine Wildman
|
